CheckMate 7FL Biomarkers
Phase III CheckMate 7FL: Biomarker Analysis of Addition of Nivolumab vs Placebo to Neoadjuvant CT and Adjuvant ET in High-Risk ER+/HER2- EBC

Released: December 08, 2023

Activity

Progress
1
Course Completed